Clinical Trial Update: Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-617 (Lu-PSMA) Treatment for Castration-resistant Metastatic Prostate Cancer [NA]

View source ↗

Summary

This clinical trial update describes evaluating intrinsic validity of molecular marker detection in tumoral DNA to predict the efficacy of Lu-PSMA-617 in metast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Lu-PSMA-617 (177Lu-PSMA-617) (lutetium-177-PSMA-617)

Snippet

Sponsor: Centre Jean Perrin | Conditions: Castration-resistant Metastatic Prostate Cancer, Treated by 177Lutetium-PSMA-617 (Lu-PSMA) | NA | Status: RECRUITING